13F HOLDINGS REPORT
Decheng Capital Management III (Cayman), LLC
Quarter ended Q2 2023 · Filed May 10, 2023 · Accession 0001104659-23-058221
Total Value
$247.9M
Positions
24
Other Managers
0
Confidential Omitted
No
Holdings (24)
| # | Issuer | Ticker / CUSIP | Shares | Value | % of Filing |
|---|---|---|---|---|---|
| 1 | Alpine Immune Sciences, Inc. | 010392595 | 6,708,288 | $51.8M | 20.89% |
| 2 | Zentalis Pharmaceuticals Inc. | ZNTL | 1,824,583 | $31.4M | 12.66% |
| 3 | 10x Genomics, Inc. | TXG | 359,554 | $20.1M | 8.09% |
| 4 | Illumnia, Inc. | ILMN | 80,859 | $18.8M | 7.59% |
| 5 | Pacific Biosciences of California, Inc. | 69404D108 | 1,463,872 | $17.0M | 6.84% |
| 6 | Cue Health Inc. | 229790100 | 8,980,909 | $16.3M | 6.59% |
| 7 | Prometheus Biosciences, Inc. | 74349U108 | 150,000 | $16.1M | 6.49% |
| 8 | Arcus BioSciences, Inc. | RCUS | 869,790 | $15.9M | 6.40% |
| 9 | Argenx SE | ARGX | 27,429 | $10.2M | 4.12% |
| 10 | Horizon Therapeutics PLC | G46188101 | 78,900 | $8.6M | 3.47% |
| 11 | Terns Pharmaceuticals, Inc. | TERN | 714,285 | $8.5M | 3.41% |
| 12 | BeyondSpring Inc. | BYSI | 4,958,143 | $5.6M | 2.24% |
| 13 | Seagen Inc. | SE | 23,014 | $4.7M | 1.88% |
| 14 | Aadi Bioscience, Inc. | WHWK | 526,329 | $3.8M | 1.54% |
| 15 | Mersana Therapeutics, Inc. | 59045L106 | 904,268 | $3.7M | 1.50% |
| 16 | Adicet Bio, Inc. | ACET | 580,000 | $3.3M | 1.35% |
| 17 | Equillium Inc. | EQ | 4,447,308 | $3.2M | 1.31% |
| 18 | Aura Biosciences, Inc. | AURA | 293,333 | $2.7M | 1.10% |
| 19 | AtriCure Inc. | ATRC | 46,259 | $1.9M | 0.77% |
| 20 | Scynexis Inc. | SCYX | 555,555 | $1.7M | 0.67% |
| 21 | GeneDx Holdings Corp. | 81663L101 | 3,418,929 | $1.2M | 0.50% |
| 22 | Apexigen, Inc. | 03759B102 | 1,894,551 | $922,646 | 0.37% |
| 23 | Owlet, Inc. | OWLTW | 898,400 | $291,441 | 0.12% |
| 24 | NeuBase Therapeutics, Inc. | 64132K102 | 1,000,000 | $185,000 | 0.07% |